Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors.

Eckhardt M, Hauel N, Himmelsbach F, Langkopf E, Nar H, Mark M, Tadayyon M, Thomas L, Guth B, Lotz R.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3158-62. doi: 10.1016/j.bmcl.2008.04.075. Epub 2008 May 1.

PMID:
18485703
3.

Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase.

Pautsch A, Stadler N, Wissdorf O, Langkopf E, Moreth W, Streicher R.

J Biol Chem. 2008 Apr 4;283(14):8913-8. doi: 10.1074/jbc.M706612200. Epub 2008 Jan 15.

4.

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.

Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F.

J Med Chem. 2007 Dec 27;50(26):6450-3. Epub 2007 Dec 1.

PMID:
18052023
5.

Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.

Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, van Meel JC.

J Pharmacol Exp Ther. 2004 Nov;311(2):502-9. Epub 2004 Jun 15.

PMID:
15199094
6.

beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition.

Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R.

Oncogene. 2004 Apr 8;23(15):2672-2680.

PMID:
14755243

Supplemental Content

Loading ...
Support Center